Central role for ENaC in development of hypertension.
Na(+) reabsorption by the epithelial Na(+) channel (ENaC) in cortical collecting duct provides the final renal adjustment to Na(+) balance, there being no further downstream Na(+) transport system. This fact coupled with the responsiveness of ENaC to aldosterone, which conveys stimulation inversely proportional to the state of Na(+) balance, places ENaC in a pivotal position to influence the risk for hypertension. Although several molecular variants of ENaC subunits have been identified, there has been no consistent demonstration of an association of any of the variants with hypertension. More compelling is the notion that ENaC activity does not fully adjust to an increase in Na(+) reabsorption occurring elsewhere in the nephron, there being overstimulation by inappropriately elevated aldosterone levels. Additional evidence that the maintenance of hypertension can be dependent on ENaC is derived from the observed responses to the treatment of hypertensive individuals with inhibitors of ENaC. Described is a clinical trial in which black hypertensive individuals who did not fully respond to more traditional therapy were given amiloride, spironolactone, a combination of the two drugs, or placebo. Treatment with either of the active inhibitors of ENaC resulted in a substantial improvement in BP. In conclusion, evidence to date is supportive of the concept that an increase in Na(+) transport by ENaC may be a common and requisite component of salt-dependent forms of hypertension.
Pratt
J Howard
JH
Department of Medicine, Indiana University School of Medicine, Richard L. Roudebush Veterans Administration Medical Center, Indianapolis, Indiana 46202-5111, USA. johpratt@iupui.edu
D000450:Aldosterone / Q000502:physiology; D000584:Amiloride / Q000627:therapeutic use*; D000959:Antihypertensive Agents / Q000627:therapeutic use; D001794:Blood Pressure / Q000187:drug effects / Q000502:physiology; D053503:Epithelial Sodium Channels; D006801:Humans; D006973:Hypertension / Q000188:drug therapy / Q000503:physiopathology*; D012307:Risk Factors; D012964:Sodium / Q000378:metabolism*; D015222:Sodium Channels / Q000502:physiology*; D013148:Spironolactone / Q000627:therapeutic use*; D019459:Urothelium / Q000502:physiology*
D000959:Antihypertensive Agents; D053503:Epithelial Sodium Channels; D015222:Sodium Channels; D013148:Spironolactone; D000450:Aldosterone; D000584:Amiloride; D012964:Sodium